Results 101 to 110 of about 1,032,308 (279)
Emerging drugs of abuse: current perspectives on synthetic cannabinoids
, 2015 Danièle Debruyne,1,2 Reynald Le Boisselier1 1Centre for Evaluation and Information on Pharmacodependence - Addictovigilance (CEIP-A), 2Toxicology and Pharmacology Laboratory, Department of Pharmacology, University Hospital Centre Côte de ...
Le Boisselier R, Debruyne D
core
Addiction, EarlyView.Abstract Aims To systematically review the evidence on the psychometric performance and accuracy of screening or diagnostic tools for cannabis use disorder. Method Systematic review and meta‐analysis which included studies conducted in clinical settings, schools, universities, community settings and population‐based surveys in multiple countries and ...
Janni Leung +8 more
wiley +1 more source
Health Risk Behaviors With Synthetic Cannabinoids Versus Marijuana
, 2017 BACKGROUND AND OBJECTIVES: Data are limited on the behavioral risk correlates of synthetic cannabinoid use. The purpose of this study was to compare the behavioral risk correlates of synthetic cannabinoid use with ...
Heather B. Clayton +4 more
core +1 more source
Beyond abstinence: Redefining success in cannabis use disorder treatment
Addiction, EarlyView.Abstract Background Over two decades of pharmacotherapy research has yet to yield a consistently effective medication for cannabis use disorder (CUD), in part because clinical trials have frequently prioritized abstinence as a primary or key endpoint.
Tobias B. Atkin +3 more
wiley +1 more source
A Case of Cannabinoid Hyperemesis Syndrome Caused by Synthetic Cannabinoids
The Journal of Emergency Medicine, 2013 Cannabinoid hyperemesis syndrome (CHS) was initially described in 2004 and remains an under-recognized clinical entity that occurs in chronic heavy marijuana smokers.We describe the first report of CHS in an abuser of synthetic cannabinoids. CHS is thought to be caused by over-stimulation of the cannabinoid 1 receptor.
unknown ( host institution ) +1 more
openaire +3 more sources
Addiction, EarlyView.Abstract Background and aims Use of derived intoxicating cannabinoid products (DICPs) has grown in the United States (US), as have associated poisonings, emergency department visits and psychotic episodes. Brand marketing on social media, a largely underregulated marketing channel, may be contributing to this growth.
Kathryn La Capria +10 more
wiley +1 more source
SYNTHETIC CANNABINOIDS: CHARACTERIZING THEIR USE AND CESSATION [PDF]
, 2019 Since their introduction to the United States in 2008, synthetic cannabinoids became the most widely used recreational drug behind marijuana, then regressed to an estimated prevalence of less than 1%. Contrary to expectations for a drug declining in use,
Turner, Richard Vernon
core
Comparison of the discriminative stimulus and response rate effects of Δ9-tetrahydrocannabinol and synthetic cannabinoids in female and male rats [PDF]
, 2017 •Female rats are more sensitive to the discriminative stimulus effects of Δ9- tetrahydrocannabinol (THC).•Synthetic cannabinoids (SCBs) produce THC-like effects in rats of both sexes.•Sex differences in rate suppressing effects do not occur for all SCBs.•
Craft, Rebecca M +3 more
core +1 more source
Addiction, EarlyView.Abstract Background and aims Over the past decade, there has been increased lifetime use of illicit and medical cannabis, underscoring the need to examine public health impacts. This includes reports of increased cannabis‐related psychosis. In this context, this study aimed to determine all cannabis‐related hospital admissions in Victoria, Australia ...
Myfanwy Graham +5 more
wiley +1 more source
Addiction, EarlyView.Abstract Background and aims Cannabis edible products are increasingly being sold on the illicit market around the world. Use of these products, typically labelled as containing Δ‐9‐tetrahydrocannabinol (THC), has been linked to adverse health effects, particularly amongst adolescents.
Matthew Gardner +9 more
wiley +1 more source